Completed PHASE2 INTERVENTIONAL 2-arm NCT00065065

A Trial of Rosiglitazone for Ulcerative Colitis

A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis

Sponsor: GlaxoSmithKline

Conditions Inflammatory Bowel Disease Ulcerative Colitis

Updated 8 times since 2017 Last updated: Dec 14, 2017 Started: Sep 30, 2002 Primary completion: Jan 31, 2008 Completion: Jan 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Inflammatory Bowel Disease and Ulcerative Colitis, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 8 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Dec 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Dec 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
James Lewis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data source: University of Pennsylvania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Boston, United States , Chevy Chase, United States , Chicago, United States , Cleveland, United States , Egg Harbor, United States , Laurel, United States , Philadelphia, United States , Plymouth, United States , Raleigh, United States and 2 more locations